Cell Therapeutics agrees to sell 15.

Related StoriesInner ear damage brain warnings from nerve cellsScalable creation of gene therapy vectors: an interview with Frank UbagsHPV study partnership signed between Beckman Coulter and IncellDx Each talk about of Series 18 Preferred Stock will have a stated worth of $1,000 per share and will be convertible at the choice of the holder, anytime to the automatic conversion of such shares using circumstances prior, into a total of 15 million shares of registered common stock at a conversion price of $1.00 per share of common stock.. Cell Therapeutics agrees to sell 15,000 shares of Series 18 Preferred Share to Quogue Capital Cell Therapeutics, Inc. today announced that it has agreed to sell 15,000 shares of its Series 18 Preferred Share right to Quogue Capital LLC and an affiliate marketer of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or positioning agent for gross proceeds of approximately $15 million .8 million.The AFA Patient Advocate stays on the line with the patient, and helps them to ask the right questions also to decipher expectations for his or her appointment. It’s like having a confident big sister who understands exactly what to do. One who says ‘take my hand, we’re going to do that jointly,’ added Ms. Madsen. When I went through my treatments, my sister have been there and I relied on her behalf strength and knowledge already. Many patients are not as fortunate, therefore the AFA is stepping up to provide this support.

Other entries from category "treatments":

Random entries